2-methyl-2,5,6,11,12,13-hexahydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one | 856693-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-methyl-2,5,6,11,12,13-hexahydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one
• 英文别名: 19-Methyl-3,13,19,20-tetraazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,21}]tricosa-1(16),2(10),4,6,8,11(15),17,20-octaen-14-one；19-methyl-3,13,19,20-tetrazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4,6,8,11(15),17,20-octaen-14-one
• CAS: 856693-61-3
• 化学式: C₂₀H₁₆N₄O
• 分子量: 328.373
• InChiKey: GOPWMXCRSJOJRB-UHFFFAOYSA-N

物化性质

• 沸点：
  759.5±60.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  62.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯吡嗪 、 2-methyl-2,5,6,11,12,13-hexahydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one 在 potassium tert-butylate 、 四丁基溴化铵 作用下， 反应 1.17h， 以52%的产率得到19-Methyl-7-pyrazin-2-yloxy-3,13,19,20-tetrazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17,20-octaen-14-one
  参考文献：
  名称：

  Novel fused pyrrolocarbazoles

  摘要：

  本发明总体上涉及选定的融合吡咯烷咔唑，包括其药物组合物及使用它们治疗疾病的方法。本发明还涉及用于制备这些融合吡咯烷咔唑的中间体和工艺。

  公开号：

  US20050137245A1
• 作为产物：
  描述：

  在 镍 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-methyl-2,5,6,11,12,13-hexahydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-one
  参考文献：
  名称：

  Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases

  摘要：

  Fused dihydroindazolopyrrolocarbazole oximes have been identified as low nanomolar, potent dual TIE-2 and VEGF-R2 receptor tyrosine kinase inhibitors with excellent cellular potency. Development of the structure-activity relationships (SAR) led to identification of compounds 35 and 40 as potent, selective dual TIE-2/VEGF-R2 inhibitors with favorable pharmacokinetic properties. Compound 35 was orally active in tumor models with no observed toxicity. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.001

文献信息

• Regioselective synthesis of 2-methyl-2,5,6,11,12,13-hexahydro 4H indazolo[5,4-a]pyrrolo[3,4-c]carbazole-4-ones
  作者：Ming Tao、Chung Ho Park、Kurt Josef、Robert L. Hudkins

  DOI：10.1002/jhet.200

  日期：2009.11

  13‐hexahydro 4H indazolo[5,4‐a]pyrrolo[3,4‐c]carbazole‐4‐one was synthesized utilizing a regioselective Diels‐Alder reaction with 5‐(1H‐indol‐2‐yl)‐2‐methyl‐6,7‐dihydro‐2H‐indazole and ethyl cis‐β‐cyanoacrylate. Acetic acid and YtBr3 were the best solvent and catalyst for the regioselective Diels‐Alder reaction. The chemistry was used to synthesize novel 8‐pyrimidinyloxy‐2,5,6,11,12,13‐hexahydro 4H

  2-甲基-2-5,6,11,12,13-六氢4H吲哚并[5,4-a]吡咯并[3,4-c]咔唑-4-酮是利用区域选择性Diels-Alder反应与5合成的-（1H-吲哚-2-基）-2-甲基-6,7-二氢-2H-吲唑和顺式-β-氰基丙烯酸乙酯。乙酸和YtBr 3是区域选择性Diels-Alder反应的最佳溶剂和催化剂。该化学方法用于合成新型8-嘧啶氧基-2,5,6,11,12,13-六氢4H吲哚并[5,4-a]吡咯并[3,4-c]咔唑-4-。被发现是DLK的有效抑制剂。J.杂环化​​学，（2009）。
• [EN] NOVEL FUSED PYRROLOCARBAZOLES<br/>[FR] NOUVEAUX PYRROLOCARBAZOLES FONDUS
  申请人：CEPHALON INC

  公开号：WO2005063763A1

  公开（公告）日：2005-07-14

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.

  本发明涉及选定的融合吡咯烷基咔唑，包括其医药组合物及用于治疗疾病的方法。本发明还涉及中间体和制备这些融合吡咯烷基咔唑的方法。
• Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
  申请人：CEPHALON FRANCE

  公开号：EP2192121A1

  公开（公告）日：2010-06-02

  The present invention relates to a method for regioselectively reducing the maleimide compounds of formula (I). The invention also relates to C7 hydroxy lactam regioisomers of formula (II) obtainable by this method and their use for the preparation of lactams of formula (Ill) which are particularly useful as intermediate for the synthesis of fused pyrrolocarbazoles.

  本发明涉及一种选择性区域还原式降低式(I)男酰亚胺化合物的方法。本发明还涉及通过该方法获得的式(II)的C7羟基内酰胺异构体及其用于制备式(III)内酰胺的应用，该内酰胺用于合成融合的吡咯烷喹啉。
• TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs
  作者：Ted L. Underiner、Bruce Ruggeri、Lisa Aimone、Mark Albom、Thelma Angeles、Hong Chang、Robert L. Hudkins、Kathryn Hunter、Kurt Josef、Candy Robinson、Linda Weinberg、Shi Yang、Allison Zulli

  DOI：10.1016/j.bmcl.2008.02.069

  日期：2008.4

  Orally bioavailable, dual inhibitors of TIE-2/VEGF-R2 were identified by elaborating the C3/N13 SAR around a fused pyrrolodihydroindazolocarbazole scaffold. Analogs bearing a C3-thiophencarbonyl group were evaluated in enzymatic and cellular biochemical assays; two orally bioavailable analogs were further pro. led in functional assays and found to inhibit microvessel growth in rat aortic explant cultures and inhibit Ang-1-stimulated chemotaxis of HUVECs. (C) 2008 Elsevier Ltd. All rights reserved.
• 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors
  作者：Robert L. Hudkins、Allison L. Zulli、Ted L. Underiner、Thelma S. Angeles、Lisa D. Aimone、Sheryl L. Meyer、Daniel Pauletti、Hong Chang、Elena V. Fedorov、Steven C. Almo、Alexander A. Fedorov、Bruce A. Ruggeri

  DOI：10.1016/j.bmcl.2010.04.021

  日期：2010.6

  A novel series of 8-(2-tetrahydropyranyl)-12,13-dihydroindazolo[5,4-a] pyrrolo[3,4-c]carbazoles (THP-DHI) was synthesized and evaluated as dual TIE-2 and VEGF-R2 receptor tyrosine kinase inhibitors. Development of the structure-activity relationships (SAR) with the support of X-ray crystallography led to identification of 7f and 7g as potent, selective dual TIE-2/VEGF-R2 inhibitors with excellent cellular potency and acceptable pharmacokinetic properties. Compounds 7f and 7g were orally active in tumor models with no observed toxicity. (C) 2010 Elsevier Ltd. All rights reserved.